BREAKTHROUGH THERAPY STATUS – EXPEDITED FDA REGULATORY APPROVAL BUT WHAT ABOUT THE PAYERS?
Author(s)
Macaulay R1, Cost P2
1PAREXEL, London, UK, 2PAREXEL, East Windsor, NJ, USA
Presentation Documents
OBJECTIVES: The breakthrough therapy pathway provides an expedited Food and Drug Administration (FDA) review where preliminary clinical evidence suggests potentially substantial clinical improvement for a serious, life-threatening condition. This has enabled regulatory approval on data packages as early as Phase 1 data (ceritinib and pembrolizumab.) We wanted to research the question of whether such clinical data would be sufficient for US payer coverage. METHODS: On 5th December 2014, publically available benefits documents were extracted from 3 national (AETNA, Anthem, and United Healthcare [UHC]) and 1 regional (Rocky Mountain) insurance companies for the 14 therapies approved by the FDA under this pathway. The coverage status, prior authorisation criteria, and price were compared. RESULTS: Most of the 14 FDA-approved drugs under the Breakthrough Therapy designation were covered by these insurers (AETNA: 10/14, UHC: 10/14, Anthem: 9/14, Rocky Mountain: 7/14). Most instances of drugs not covered reflect those approved very recently. However, the majority were subject to prior authorizations (AETNA: 10/10, Anthem: 9/9, UHC: 5/10, Rocky Mountain: 7/7). These prior authorizations sometimes included clinical criteria more stringent than those in the FDA label (15/31 similar to FDA label, 9/31 slightly more restrictive, 7/31 much more restrictive). The drugs most frequently subject to much greater restrictions than the FDA label were Sovaldi and Harvoni. The level of restrictions were not seemingly related to the patient cost per treatment which ranged up to $307,000 (Kalydeco) but rather seemed correlated with budget impact (very large with Sovaldi and Harvoni, indicated for Hepatitis C). CONCLUSIONS: Breakthrough status can result in early US payer approval in addition to regulatory approval. Insurers may place additional restrictions through prior authorizations but this relates more to the budget impact of the drugs than the cost per patient or level of supportive clinical evidence.
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PHP26
Topic
Economic Evaluation, Health Policy & Regulatory, Health Service Delivery & Process of Care, Health Technology Assessment
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Decision & Deliberative Processes, Formulary Development, Health Care Research, Pricing Policy & Schemes, Reimbursement & Access Policy
Disease
Multiple Diseases
Explore Related HEOR by Topic